Las mutaciones en el cáncer de pulmón: EGFR, KRAS, METex14 y más

Lung cancer isn’t just one diseaseit’s more like a whole neighborhood of diseases that share the same street name. And the “house number” often comes down to mutations: specific DNA changes inside tumor cells that can influence how fast a cancer grows, how it behaves, and (most importantly) which treatments are most likely to work.

In the U.S., testing for key lung cancer mutations has reshaped care for many people with non-small cell lung cancer (NSCLC), especially adenocarcinoma. If you’ve heard terms like EGFR, KRAS, or MET exon 14 skipping (METex14) and thought, “Are these Wi-Fi passwords?”you’re not alone. Let’s translate the alphabet soup into something you can actually use.

Quick note: This article is educational and not medical advice. Treatment choices should be made with an oncology team that knows the details of the case.

What “mutation” means in lung cancer (and why you should care)

A cancer mutation is a change in DNA that helps tumor cells survive, multiply, and dodge normal “stop growing” signals. In lung cancer, some mutations act like a stuck gas pedal. These are often called driver mutations because the tumor is “driven” by that pathway.

Why does that matter? Because if you can identify the driver, you may be able to use a targeted therapya drug designed to block that specific signal. In many cases, this can mean:

• More precise treatment (aimed at the tumor’s biology)
• Higher response rates than older one-size-fits-all approaches
• Oral medications for some mutations (not always, but often)
• Different side-effect profiles than traditional chemotherapy

The “must-do” step: biomarker testing (aka molecular profiling)

If NSCLC is advanced (locally advanced or metastatic), biomarker testing is a big dealbecause you can’t target what you haven’t identified. Testing can include:

Tissue testing (biopsy-based)

This uses a sample of tumor tissue. Many centers use next-generation sequencing (NGS) panels that check for many mutations at once. Tissue testing can also assess tumor type and help confirm diagnosis.

Liquid biopsy (blood-based)

This looks for tumor DNA fragments circulating in the blood. It can be faster and easier when tissue is limited, and it’s especially helpful when doctors are looking for resistance mutations after a treatment stops working. A negative blood test doesn’t always rule out a mutation, so clinicians may still recommend tissue testing depending on the situation.

Key takeaway

In modern lung cancer care, the question is often not just “What stage is it?” but also “What’s the molecular profile?”because that profile may open doors to targeted drugs or clinical trials.

Major lung cancer mutations explained (EGFR, KRAS, METex14, and friends)

EGFR: a classic target with constantly evolving options

EGFR (epidermal growth factor receptor) mutations are among the best-known drivers in NSCLC. They’re more common in adenocarcinoma and can occur in people with little or no smoking history (though smoking history doesn’t “exclude” EGFR).

The most common actionable EGFR mutations include exon 19 deletions and exon 21 L858R. When a tumor has one of these, targeted EGFR drugscalled tyrosine kinase inhibitors (TKIs)are often a central part of treatment.

Real-world example

Imagine two people with the same scan findingsboth metastatic adenocarcinoma. One tumor has an EGFR exon 19 deletion. The other does not. Their first-line treatment plans may look very different, because the first person might benefit from an EGFR-targeted approach right away.

What treatment conversations often include

• First-line EGFR-targeted therapy for exon 19/L858R
• Combination approaches (for some patients) that pair targeted drugs to deepen response
• Planning ahead for resistance, because cancers can adapt over time

Resistance (the plot twist): Even when targeted therapy works well, tumor cells can evolve. Resistance mechanisms may include additional EGFR changes (like certain alterations affecting drug binding) or “bypass tracks” such as MET amplification. When that happens, clinicians often re-test (tissue or blood) to guide the next step.

KRAS: once “undruggable,” now very much in the chat

KRAS mutations are common in NSCLC, particularly in adenocarcinoma. For years, KRAS was considered notoriously difficult to targetlike trying to grab a greased watermelon. But therapies targeting KRAS G12C have changed that story.

KRAS G12C is a specific KRAS subtype. If a tumor has this mutation, there are targeted inhibitors that may be usedoften after prior systemic therapy, depending on the clinical context and evolving standards of care.

Why KRAS still isn’t “simple”

• Not all KRAS mutations are the same (G12C is just one subtype).
• KRAS tumors may have other co-mutations that influence behavior and response.
• Treatment strategy can vary based on prior therapies, overall health, and tumor burden.

Practical takeaway: If you hear “KRAS-positive,” ask which KRAS mutation it is. That one detail can change whether targeted therapy is on the table.

MET exon 14 skipping (METex14): a small splice change with big impact

METex14 refers to a change in how the MET gene is “spliced” when making its protein. Skipping exon 14 can lead to excessive MET signaling, which can drive tumor growth.

METex14 is important because there are FDA-approved MET inhibitors specifically for NSCLC with MET exon 14 skipping alterations. That’s the hallmark of a clinically useful biomarker: it’s not just interestingit’s actionable.

What METex14 discussions often include

• MET-targeted therapy options
• Side-effect monitoring (each drug class has its own “watch list”)
• Re-testing at progression to identify resistance pathways

ALK: a key driver, especially in younger or never-smokers

ALK rearrangements can drive NSCLC and are strongly linked with targeted therapy choices. Multiple generations of ALK inhibitors exist, and therapy selection often considers brain metastasis risk, side effects, and resistance patterns.

ROS1: rare but highly actionable

ROS1 fusions are uncommon, but when present they can be treated with targeted ROS1 inhibitors. Because ROS1-positive NSCLC often affects people with little or no smoking history, testing mattersmissing it can mean missing a targeted option.

RET: another fusion with dedicated targeted drugs

RET fusions are a well-established actionable target in NSCLC. When identified, RET inhibitors can become a central part of the treatment plan.

BRAF V600E: a mutation with a proven combo approach

BRAF V600E is better known in melanoma, but it’s also found in a subset of NSCLC. Targeting BRAF often involves a combination strategy (BRAF inhibitor plus MEK inhibitor) to improve response and delay resistance.

HER2 (ERBB2): from “interesting” to increasingly targetable

HER2 (ERBB2) mutations can drive NSCLC, and treatment options have expanded. Historically, antibody-drug conjugates became an important option for HER2-mutant NSCLC after prior therapy. More recently, additional HER2-targeted approachesespecially for certain HER2 tyrosine kinase domain (TKD) activating mutationshave entered the landscape.

NTRK fusions: rare, but the definition of “test broadly”

NTRK gene fusions are uncommon in lung cancer, but they have tumor-agnostic targeted treatments. That means the drug is approved based on the mutation across many cancer types, not one location in the body.

What if no “driver” mutation is found?

If testing doesn’t identify an actionable driver, treatment decisions often lean on other biomarkers and clinical factors, such as:

• PD-L1 expression (which can guide immunotherapy decisions)
• Overall health and performance status
• Tumor burden and symptoms
• Histology (adenocarcinoma vs squamous)

For many patients without an actionable driver mutation, immunotherapy (sometimes with chemotherapy) becomes a key option. But if a strong driver mutation is present (like EGFR), immunotherapy strategy can differanother reason why mutation testing first is so important.

Why results can take time (and why that wait is often worth it)

Waiting for biomarker results can feel like watching a loading bar that refuses to move. But choosing treatment before you have the mutation profile can mean starting a regimen you’d replace immediately once results come back.

Many oncology teams balance this by managing symptoms, stabilizing urgent issues, and moving testing forward quicklyso the first major treatment decision is made with the best information available.

Questions to bring to your next appointment (no lab coat required)

• Which biomarkers were tested? Was it a broad NGS panel?
• Do I have any actionable mutations (EGFR, KRAS G12C, METex14, ALK, ROS1, RET, BRAF, HER2, NTRK)?
• If tissue was limited, should we add a liquid biopsy?
• If a targeted therapy is recommended, what are the most common side effects and how do we monitor them?
• What is the plan if the cancer develops resistancewill we re-test?
• Are there clinical trials that fit my mutation profile?

Conclusion

Understanding lung cancer mutationsespecially EGFR, KRAS, and METex14turns a scary, vague diagnosis into something more specific and, in many cases, more treatable. Biomarker testing helps identify whether a tumor has a “driver” that can be blocked with targeted therapy, whether immunotherapy is likely to play a big role, and what clinical trials might fit.

In plain English: mutations help personalize treatment. And in lung cancer, personalization isn’t a luxuryit’s often the difference between “standard” and “strategic.”

Real-world experiences (about ): what patients and caregivers often describe

Even when the science is crystal clear, the experience of living through biomarker testing and targeted therapy can feel… less like a documentary and more like an unscripted reality show with surprise plot twists.

First comes the waiting. Many people describe the time between diagnosis and mutation results as one of the most emotionally intense parts of the journey. Scans might already show “where” the cancer is, but the mutation test determines “how” it behavesand which treatments might actually match it. Patients often say it helps to treat this period like a planning phase: make a list of questions, ask what symptoms should trigger an urgent call, and lean on a friend or family member to take notes during appointments. (Because stress has a way of deleting memories like a mischievous toddler with your phone.)

Then comes the vocabulary explosion. People frequently talk about the shock of learning a new language overnight: exon 19 deletions, L858R, METex14, KRAS G12C, ALK fusions. A common coping strategy is to focus on the practical translation: “Is there a targeted treatment for this mutation?” and “What’s our plan A, B, and C?” Some patients keep a simple one-page “cheat sheet” with their mutation, current therapy, side effects to watch for, and the date of the last scanuseful for every clinic visit and any second opinion.

Targeted therapy can feel surprisingly normaluntil it doesn’t. Many targeted treatments are pills, which can be a relief compared with frequent infusion visits. Patients often describe a new rhythm: taking medication daily, checking labs, and learning side-effect management. For EGFR therapies, for example, people commonly talk about skin changes (like acne-like rash) and diarrhea, and how early communication with the care team can prevent small problems from becoming big ones. With MET inhibitors, patients may mention swelling or fatigue. Everyone’s experience differs, but the recurring theme is that side effects are often manageable when addressed early.

Scans bring “scanxiety,” even when things are going well. It’s common for people to feel nervous before follow-up imagingbecause that’s when you find out if the treatment is still working. Many patients say it helps to schedule something comforting after scan appointments (a favorite meal, a low-key outing, a movie night) so the day isn’t only about waiting for results.

Resistance can feel discouragingbut it’s also a roadmap. When a therapy stops working, patients often describe an initial drop in confidence: “Did we run out of options?” In reality, progression frequently triggers the next smart move: re-testing (tissue or blood), identifying resistance mechanisms, and switching to a new targeted therapy, combination approach, chemotherapy, immunotherapy strategy, or a clinical trial. Many people find hope in the idea that lung cancer treatment is increasingly a series of well-informed stepsnot a single do-or-die moment.

If you take one message from these experiences, let it be this: the science is powerful, but your quality of life matters just as much. Ask questions, report symptoms early, and don’t be shy about supportbecause nobody wins an endurance race by refusing water.